Search
for
Sort by
Research 61–90 of 1000+
- Mechanisms of autophagy and their implications in dermatological disorders
- II Consensus of the Brazilian Society of Dermatology for the treatment of alopecia areata
- Dissecting Cellulitis of the Scalp: Linking Pathogenesis to Therapy
- Netherton syndrome subtypes share IL-17/IL-36 signature with distinct IFN-α and allergic responses
- 695 Selectively targeting JAK1 or JAK3 pathway is sufficient to reverse alopecia areata
- Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
- Janus Kinase inhibitors in dermatology: a review
- Various Applications of Tofacitinib and Ruxolitinib (Janus Kinase Inhibitors) in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective
- Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
- Efficacy of Janus kinase inhibitors in adult patients with alopecia areata
- Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis
- Tumor necrosis factor inhibitors and janus kinase inhibitors in the treatment of cicatricial alopecia: A systematic review
- JAK kinase pathway inhibitor drugs in patients with moderate-to-severe alopecia: a real-world experience
- Treatment of alopecia universalis with topical Janus kinase inhibitors – a double blind, placebo, and active controlled pilot study
- Targeted immunotherapy for hair regrowth and regeneration
- Recalcitrant alopecia areata responsive to leflunomide and anthralin—Potentially undiscovered JAK/STAT inhibitors?
- Role of janus kinase inhibitors in the treatment of alopecia areata
- Exploring the efficacy of baricitinib in treating alopecia areata after failed Janus kinase inhibitor therapy
- A review of Janus kinase inhibitor use in scarring alopecia
- The Current State of Patient Adherence to Lab Monitoring Guidelines for Janus Kinase Inhibitors in Patients with Alopecia Areata.
- Analyzing the role of tofacitinib in treatment of alopecia areata: A retrospective analysis from a tertiary care center of North India
- THE USE OF TOFACITINIB IN THE TREATMENT OF IMMUNE-MEDIATED UNIVERSAL ALOPECIA IN A PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A CASE REPORT
- Selective Janus kinase 1 inhibition resolves inflammation and restores hair growth offering a viable treatment option for alopecia areata
- Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo
- Drugs targeting the JAK/STAT pathway for the treatment of immune-mediated inflammatory skin diseases: protocol for a scoping review
- Improvement of Psoriasis, Psoriatic Arthritis, and Alopecia Universalis during Treatment with Tofacitinib: A Case Report
- Janus kinase inhibitors for alopecia areata: A narrative review
- An urticarial drug eruption caused by tofacitinib for alopecia universalis
- Suspected upadacitinib-associated drug hypersensitivity mimicking disease exacerbation in ulcerative colitis
- Perspectives of Chinese Adult Patients with Alopecia Areata on Janus Kinase Inhibitors Therapy: A Qualitative Analysis Based on Social Media Platforms